Company Overview
Xtant Medical Holdings, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry by providing regenerative medicine products and specialized equipment for orthopedic and neurological surgeons in both domestic and international markets. The company's core offerings include the OsteoSponge, a natural scaffold designed to facilitate cellular in-growth, and the OsteoSelect DBM Putty, a product capable of being compressed to fit specific anatomical needs. In terms of operational scale, Xtant Medical Holdings, Inc. maintains a market capitalization of $77.42M while generating annual revenue of $133.08M with a workforce consisting of 217 employees. These financial figures position the company as a mid-cap entity with a substantial revenue base relative to its employee count, suggesting significant operational efficiency or high-value product pricing structures that allow it to sustain a $133.08M revenue stream with a relatively lean team of 217 personnel.
Financial Health
The company reported a trailing twelve-month revenue of $133.08M, with a corresponding net income of $1.75M and an EBITDA of $10.90M. The substantial disparity between the $133.08M revenue and the $1.75M net income highlights a cost structure where operating expenses, taxes, or interest obligations consume a significant portion of the top line, leaving a profit margin of only 1.3%. Despite the low net income, the company generated positive free cash flow of $9.42M, which indicates a strong ability to generate cash from operations that exceeds capital expenditures, thereby providing financial flexibility for potential reinvestment or debt reduction. The gross margin stands at 62.0%, reflecting the high value-added nature of the medical devices, while the operating margin of 7.6% and the thin profit margin of 1.3% reveal the intensity of competitive pressures or high fixed cost environments typical in the medical device sector. On the balance sheet, Xtant Medical Holdings, Inc. holds $10.40M in cash against $32.49M in total debt, resulting in a debt-to-equity ratio of 64.48 which signifies a leveraged position where debt obligations exceed equity capital. However, the current ratio of 2.21 suggests that the company maintains a conservative approach to short-term liquidity, holding more than double the value of current assets relative to its current liabilities. Return on Equity is recorded at 3.6% and Return on Assets at 3.9%, metrics that indicate that management effectiveness in generating returns on shareholder equity and total assets is currently limited, likely due to the high leverage and low net income figures relative to the asset base.
Valuation Assessment
The trailing P/E ratio is 55.30, while the forward P/E is -11.06, a divergence that implies the market expects earnings to be negative in the immediate future or that current earnings do not reflect upcoming operational shifts. The price-to-book ratio is 1.54, indicating that the stock trades at a 54% premium over its book value, which may reflect market confidence in the company's intangible assets or future growth potential despite current earnings constraints. Alternative valuation metrics such as the price-to-sales ratio of 0.58 and an EV/EBITDA of 9.13 suggest that the company is valued conservatively relative to its sales and earnings before interest, taxes, depreciation, and amortization, particularly when considering the negative forward earnings estimate. The 52-week trading range spans from a low of $0.34 to a high of $0.95, providing context for the stock's recent price volatility and historical price action within this specific year. The beta value is -0.17, which is an unusual negative figure indicating that the stock price has historically moved inversely to the broader market, displaying volatility characteristics that differ significantly from the standard positive correlation observed in most healthcare equities.
Growth & Income
Revenue growth is currently standing at 19.0% year-over-year, whereas earnings growth is listed as N/A due to the negligible net income relative to the revenue base. The absence of a meaningful earnings growth rate relative to the robust revenue expansion implies that the company is prioritizing market share capture or product line expansion over immediate profitability enhancement. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are retained within the business to fund operations, research, or debt management rather than being distributed to shareholders. The overall growth and income profile is characterized by strong top-line expansion driven by a 19.0% revenue increase, coupled with a strategy of zero dividend distribution and a reliance on retained earnings to support the company's financial trajectory.